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AbstrAct
Although originally identified for its function in Drosophila melanogaster eye 
specification, the Retinal Determination Gene Network (RDGN) is essential for the 
development of multiple organs in mammals. The RDGN regulates proliferation, 
differentiation and autocrine signaling, and interacts with other key signaling 
pathways. Aberrant expression of RDGN members such as DACH, EYA and SIX 
contributes to tumor initiation and progression; indeed, the levels of RDGN members 
are clinically prognostic factors in various cancer types. Stimulation or suppression of 
the activities of these crucial components can block cancer cell proliferation, prevent 
cancer stem cell expansion and even reverse the EMT process, thereby attenuating 
malignant phenotypes. Thus, cancer therapeutic interventions targeting RDGN 
members should be pursued in future studies.
INtrODUctION 
Developmental programs control physiological 
functions at early growth stages, including cell 
proliferation, differentiation, morphogenesis and tissue 
homeostasis. Aberrant activation of such programs may 
disturb the homeostatic balance and thereby trigger 
tumorigenesis. In this respect, a regulatory network 
called the Retinal Determination Gene Network (RDGN), 
originally identified as a fundamental signal for Drosophila 
melanogaster eye specification, may also be dysregulated 
in cancer [1, 2]. Functional modification of the key RDGN 
members, DACH, EYA and SIX, is a potential therapeutic 
approach to individualized chemotherapy.
rDGN sIGNALING, FrOM DrOsOPHILA 
EYE DEVELOPMENt tO HUMAN 
DIsEAsE
The RDGN first received attention as a key signaling 
pathway in Drosophila eye determination [3]. In the last 
fifteen years, RDGN signaling has been shown to govern 
the specification of a wide range of tissues, including the 
retinas of both insects and mammals. This regulatory 
network mainly includes a structural relative of the Ski/
Sno gene family, dachshund; the SIX family members, 
sine oculis (so) and optix; the tyrosine phosphatase, 
eyes absent (eya); and the Pax6 homologs, eyeless (ey) 
and twin of eyeless (toy). These genes are organized in 
a sophisticated network that controls organogenesis, and 
mutations of these genes in humans are associated with 
several clinical disorders [3]. 
                                                         Review
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The mammalian DACH1 protein can inhibit target 
gene expression either directly, by binding to specific 
DNA sequences within chromatin [4, 5], or indirectly, by 
combining with other transcription factors (c-Jun, SMADs 
and SIX) [6-9]. For example, DACH1 can displace 
FOXM1 and FOXC2 from the cis elements within 
promoters that have Forkhead family binding sites and 
thereby attenuate their oncogenic activity [4, 5]. During 
vertebrate development, DACH1 function is required 
for organ specification [8, 10-12]. In humans, DACH1 
germline mutations have been shown to contribute to 
bilateral cystic renal dysplasia [13], chronic kidney disease 
(CKD) [14], familial young-onset diabetes, pre-diabetes 
and cardiovascular diseases like coronary heart disease 
(CHD) and coronary arteriosclerosis [15]. DACH1 also 
inhibits aldosterone secretion in zona glomerulosa cells 
[16]. However, the functional significance of DACH1 in 
human diseases still remains a mystery.
As a member of the homeobox gene family, the 
SIX superfamily has been evolutionarily conserved, and 
controls embryonic development and tissue specification 
of the eye, kidney and muscle [2, 3, 17]. During the early 
stages of development, Six1 activates a diverse range of 
target genes that determine the proliferation and survival 
of progenitor cells. Once organ development is complete, 
Six1 is maintained at low or even undetectable levels in 
adult tissues [18]. Proteins of the SIX family have two 
regions of high sequence conservation: the homeoprotein 
domain (HD) and the SIX domain (SD). SIX proteins 
recognize specific DNA sequences, and both the HD and 
the SD contribute to these DNA interactions [19, 20]. 
Nevertheless, the transcriptional function of SIX depends 
on an additional cofactor within the complex. For instance, 
Dach1 functions as a corepressor to inhibit the expression 
of Six target genes, whereas Eya permits Six to activate 
downstream signaling [8].
 As another component of the conserved RDGN, 
the EYA family proteins are important transcriptional 
cofactors. Generally, Eya is recruited to the local 
chromatin of target genes through Six proteins [8]. 
Structural analyses have revealed that SIX1 binds to EYA 
through a single amphipathic helical structure, and that 
even a single amino acid substitution can abolish SIX1-
induced epithelial-mesenchymal transition (EMT) [19]. 
In humans, mutations in SIX and EYA or disruption of 
the SIX/EYA complex cause branchio-oto-rena (BOR) 
syndrome, an autosomal dominant genetic disorder 
marked by underdeveloped or absent kidneys, deafness, 
auricular malformations and bronchial arch remnants [19, 
21, 22]. The function of SIX/EYA complex is also required 
for lung morphogenesis [23] and myocardial hypertrophy 
[24]. Thus, abnormal functioning of the SIX/EYA complex 
may impact a broad range of human diseases. 
Another critical feature that separates EYA proteins 
from other RDGN members is their tyrosine/threonine-
phosphatase activity. The phosphatase activity of Eya 
bridges Dach and Six, and switches Six-Dach from a 
repressed to an activated state by displacing a corepressor 
and recruiting a coactivator [8]. The conserved carboxy-
terminal domain of EYA (ED) is essential for protein-
protein interactions, for instance, with SIX and DACH. 
EYA has been classified into the haloacid dehalogenase 
(HAD) superfamily based on signature motifs in the 
ED, and functions as an Mg2+-dependent tyrosine 
phosphatase. The N-terminal region (commonly referred 
to as ED2), which is characterized by a rich stretch of 
proline/serine/threonine residues, is mainly responsible 
for threonine dephosphorylation [2]. This region also 
provides transactivation domain during Drosophila 
eye development [25]. Because of this phosphorylation 
mechanism, the EYA family participates significantly in 
the cellular response to changes in the microenvironment, 
but the influences of individual family members vary 
because of their different phosphatase activities. For 
example, by dephosphorylating H2AX at tyrosine 142 
(pY142), EYA1, EYA2 and EYA3 regulate the formation 
of γH2AX, which promotes DNA repair and cell survival 
and thus prevents genotoxic stress-induced apoptosis 
[26, 27]. In the innate immune response, EYA4 serves 
as a threonine phosphatase rather than as a tyrosine 
phosphatase [28]. The phosphatase activity of EYA is 
essential for the maintenance of tight junctions in lung 
epithelial cells [29]. However, in breast tumors, EYA2 
dephosphorylates estrogen receptor β (ERβ) at Y36, thus 
reversing its antitumor role and promoting malignant 
growth and dissemination [30]. Likewise, the tumorigenic 
role of EYA1 in breast cancer cells relies on its 
phosphatase function [31]. Thus, the phosphatase activity 
of EYA may be a good target of cancer therapeutics.
Recent studies have revealed the significance 
of the RDGN in tumorigenesis and tumor progression 
[1, 2]. DACH1 is a tumor suppressor, while SIX/EYA 
promote malignancy, so aberrations in these components 
of the RDGN signaling machinery enable cells to acquire 
oncogenic properties. For example, inactivation of 
DACH1 or hyperactivation of SIX/EYA in breast epithelial 
cells leads to over-proliferation, tumor formation and 
invasion into blood vessels, resulting in distant metastases 
(Figure 1). These activities of the RDGN members will be 
discussed in detail below.
tHE rDGN IN tUMOr INItIAtION AND 
PrOGrEssION
Proliferation and cancer stem cells
Constitutive mitogenic signals drive the 
misexpression of key cell cycle machinery, leading to 
the initiation and progression of tumorigenesis [32]. 
The RDGN maintains a dynamic balance that controls 
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progression through the cell cycle. Suppression of 
cyclin D1 and cyclin A by DACH1 negatively regulates 
cell cycle progression [33, 34] and thereby blocks 
cellular proliferation and tumor growth in various 
cancers [33-35]. In contrast, EYA1 induces cyclin D1 
through its phosphatase activity in breast cancer, and 
SIX1 directly enhances the transcription of cyclin D1 
in rhabdomyosarcoma tumor cells [31, 36]. SIX1 also 
active cyclin A1 expression to promote proliferation; 
furthermore, SIX1 alone can transform mammary 
epithelial cells and promote aggressive tumor formation 
and peritumoral lymphovascular invasion [37]. DACH1 
promotes cell cycle arrest through context-dependent 
interactions with p53 and activating p53-taget genes [38, 
39], whereas SIX1 downregulates p53 by upregulating 
microRNA-27a-3p and downregulating ribosomal protein 
L26 (RPL26) [40]. Imbalance between the tumor-
restraining effect of DACH1 and the oncogenic functions 
of SIX/EYA accelerates cell cycle progression and 
attenuates apoptosis, creating a favorable environment for 
uncontrolled proliferation.
Cancer stem cells (CSCs), also called tumor 
initiation cells (TICs), are characterized by self-renewal 
and differentiation, and contribute to therapeutic 
resistance. The regulation of breast CSCs by DACH/
EYA/SIX is now well documented. A subpopulation 
of cells with the CD44high/CD24low signature, (where 
CD44 and CD24 are widely recognized cell surface 
markers for breast CSCs [41]), can either be negatively 
regulated by DACH1 as it antagonizes NANOG, KLF4 
and SOX2 transcriptional activation [42], or positively 
enriched by SIX1/EYA1 overexpression [43]. SIX1 also 
activates TGF-β and MAPK signaling to enhance the 
accumulation of CSCs [43, 44]. In a bitransgenic mouse 
model, overexpression of human SIX1 in the adult mouse 
mammary gland epithelium was found to induce tumors 
of multiple histological subtypes and to promote stem/
progenitor cell characteristics by activating Wnt signaling 
[45]. Similar to SIX1, EYA1 (through its phosphatase 
activity) allows the proportion of breast CSCs to increase 
[31]. The therapeutic potential of the RDGN to limit the 
population of TICs is substantial.
the rDGN governs EMt and metastasis
EMT, the transformation of epithelial cells into cells 
with a mesenchymal migratory phenotype, participates 
in embryonic tissue formation, but also contributes to 
Figure 1: A. RDGN members determine breast cancer initiation and progression. In normal breast epithelial cells, the functional balance 
of DACH and SIX/EYA maintains homeostasis in luminal cellular proliferation/apoptosis and thereby maintains the luminal structure. 
Functional loss of DACH or hyperactivity of SIX/EYA drives hyper-proliferation, transformation, and progression to ductal carcinoma in 
situ. Some malignant cells undergo EMT, acquire cancer stem cell properties, invade through the basal membrane and enter blood vessels, 
leading to distant metastases. “↑” represents an upregulated function and “↓” represents a downregulated function.
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tumor progression. An interactive network including 
multiple signaling pathways and post-transcriptional 
factors facilitates the changes in epithelial cells that 
drive metastatic seeding [46, 47]. TGF-β-driven cell 
reprogramming is a multistep process that passes first 
through EMT. The activation of Wnt signaling creates 
a favorable environment for TGF-β-induced EMT [48]. 
The cross-talk between RDGN and Wnt/TGF-β signaling 
promotes EMT (Figure 2).
DACH1 was first shown to inhibit TGF-β signaling 
by binding to SMAD4 in breast cancer [49]. Subsequently, 
DACH1 was found to restrain TGF-β/SMAD-induced 
EMT [50]. DACH1 may also antagonize EMT in part by 
inactivating Wnt/β-catenin signaling; indeed, DACH1 was 
recently found to downregulate β-catenin in hepatocellular 
and gastric cancer [35, 51]. In contrast, SIX1 promotes 
EMT in a TGF-β signaling-dependent manner, and is a 
critical enhancer in the switch of TGF-β/SMAD from 
tumor suppressors to oncogenic proteins [44, 52, 53]. 
Even a single amino acid mutation in SIX1 disrupts the 
SIX1-EYA2 complex, thereby abolishing SIX1-dependent 
TGF-β signaling and EMT progression [19]. In addition, 
SIX1-enhanced tumorigenesis is coupled to Wnt signaling 
activation [53]. EYA2 inactivation reverses the activation 
of TGF-β/SMAD and EMT induced by SIX1 [54].
The RDGN also governs EMT by regulating the 
expression of EMT-associated genes. DACH1 was 
found to abolish YB-1-induced SNAI1 translation 
and thus reverse EMT in basal-like breast cancer, an 
aggressive subtype [55]. By downregulating SNAI1, 
DACH1 increases E-cadherin expression and induces 
morphological changes that enhance epithelial properties 
[56]. SIX1 suppresses miR-200-family expression, a 
negative feedback loop in ZEB1/ZEB2 regulation, which 
in turn promotes EMT and carcinogenesis [57]. The role 
of EYA in EMT remains to be understood. The tyrosine-
Figure 2: targeting the DAcH/sIX/EYA pathway in cancer treatment. TGFβ and Wnt signaling are both critical for tumor 
initiation and progression. Generally, SIX/EYA activates these two signaling pathways, whereas DACH1 negatively regulates them. The 
function of SIX could be blocked by the silencing of SIX expression with shRNA, or by the disruption of the SIX/EYA complex with 
small molecules. EYA phosphatase activity could be blocked by biochemical inhibitors. On the other hand, DACH1 expression could be 
reactivated with demethylating agents or miRNA. Thus, targeting RDGN members is a promising therapeutic strategy that could restrain 
malignant behavior in tumors.
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phosphatase activity of EYA3 was shown to be critical for 
cell motility and invasiveness rather than proliferation, 
indicating that EYA3 promotes metastatic behavior in 
cancer cells [58]. However, our previous study also 
indicated that transactivation of cyclin D1 through the 
tyrosine-phosphatase activity of EYA1 is required for 
tumor growth and cellular proliferation [31]. Some of 
these inconsistent results are due to the fact that different 
researchers have tested the phosphatase activities of the 
EYAs in different breast cancer cell lines. Although the 
EYA family members may behave distinctly in different 
studies, their underlying mechanisms may overlap. 
Whether they share similar functions during cancer 
development needs to be further examined.
the regulation of the tumor microenvironment by 
rDGN signaling
In response to oncogenic signals from solid 
tumors or evolving genetic/epigenetic alternations, the 
tumor microenvironment continually changes to support 
malignant behavior. Numerous components participate 
in this process, but cancer-related inflammation and 
dysregulation of innate immunity especially disturb the 
physiological homeostasis. It has been indicated that 
DACH1 binds the endogenous IL-8 promoter to block 
breast cancer cellular migration in vitro and metastasis 
in vivo [59]. Dach1 gene deletion in mice was shown 
to dramatically increase IL-8 and IL-6 abundance by 
nearly 1000-fold and thus promote prostate cancer 
cellular migration [60]. CXCL5 is another downstream 
target whereby DACH1 inhibits lung tumorigenesis and 
metastasis [61]: endogenous DACH1 negatively regulates 
CXCL signaling to inhibit cytokine secretion and restrain 
malignant cell growth and migration. DACH1 also was 
found to repress bFGF-induced tumor initiation in glioma 
cells [62]. In contrast, as an enhancer of the innate immune 
response, EYA4 induces IFN-β and CXCL10 expression 
by phosphorylating IRF3 and activating NF-κB to against 
the undigested DNA from apoptotic cells [28]. While the 
involvement of SIX1 in cytokine secretion and immune 
regulation is yet to be established, the current evidence 
suggests that an imbalance in the RDGN would create a 
favorable microenvironment to enhance the survival of 
cancer cells and their escape from the primary tumor.
Tumor-associated angiogenesis is another crucial 
step early in the development and growth of most solid 
neoplasms, and is also necessary for the hematogenous 
dissemination of cancer cells. Indeed, EYAs have been 
detected in vascular endothelial cells and enhance 
sprouting angiogenesis, mainly by their tyrosine-
phosphatase activity [63]. This may explain why 
transgenic Eya knockout mice are characterized by serious 
defection in the smooth muscle component of the bronchi 
and pulmonary vessels [64]. Although EYAs promote 
vascular development, it remains unclear whether they 
function similarly in endothelial cells and vascular smooth 
muscle cells.
To invade distant organs, cancer cells must 
either enter the blood or lymphatic vasculature. The 
changes in lymphatic vessels can be detected even in 
early tumor initiation; for instance, the expression of 
vascular endothelial growth factor C (VEGF-C), a key 
promoter of lymphangiogenesis, is enhanced at this 
stage. SIX1 promotes lymphangiogenesis and lymphatic 
metastasis by upregulating VEGF-C expression [65, 
66]. SIX1 transcriptionally activates VEGF-C [65], and 
overexpression of SIX1 in tumor cells may abrogate the 
inhibitory effect of TGF-β on lymphangiogenesis by 
upregulating VEGF-C [66]. Considering that EYA2 is an 
indispensable coactivator in SIX1-induced TGF-β signal 
activation [19], EYA2 may participate in promoting 
lymphangiogenesis in a SIX1-dependent manner.
POtENtIAL strAtEGY OF tArGEtING 
tHE rDGN PAtHWAY FOr cLINIcAL 
bENEFIt
Successful cancer drugs can be designed against 
specific molecular targets involved in proliferation, 
invasion, metastasis and TIC formation [67, 68]. However, 
discovering novel drug targets is challenging because the 
inhibition or activation of target genes expressed in normal 
tissue may result in nonspecific toxicity. Targeting RDGN 
members like SIX/EYA, which are silent or expressed 
at low levels in adult tissue but are overexpressed in 
tumors, is a tremendous opportunity for such anticancer 
therapy. The tyrosine-phosphatase activity of EYA is 
significant because it promotes DNA damage repair [26] 
and tumor growth [31], which may promote relapse from 
chemotherapy and ionizing radiation. Thus, a combination 
therapy including highly selective EYA inhibitors would 
reduce the incidence of chemotherapy resistance. 
Alternatively, reactivation of DACH1 expression could 
restrain tumor growth and metastasis [59]. Therefore, 
therapies co-targeting RDGN members may be more 
effective and durable cancer treatments than existing 
treatment options (Figure 2). 
DAcH1
Reduced expression of DACH1 tightly correlates 
with poor prognosis in breast cancer, as was first 
demonstrated in a tissue microarray analysis of over 2,100 
samples, and was subsequently supported in an artificial 
neural network (ANN) approach [33, 69]. Reduced 
DACH1 expression also correlates with poor prognosis 
in prostate cancer and lung and hepatocellular carcinoma 
patients [35, 59, 70]. Using Dach1 gene deletion, Dach1 
was shown to inhibit prostate cellular proliferation in vivo 
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[60]. Still, whereas a number of studies have demonstrated 
that DACH1 profoundly improves the prognosis of cancer 
patients as a tumor suppressor, a few studies have also 
observed an oncogenic role of DACH1 in endometrial 
cancer and mixed lineage leukemia (MLL) [2, 24, 71]. 
These seemingly disparate findings might indicate that the 
exact function of DACH1 depends on its communication 
with specific signaling pathways, especially in the context 
of organ heterogeneity. 
Various studies have explored the potential of 
restoring DACH1 expression in cancer cells. Epigenetic 
silencing of the DACH1 promoter region is often 
responsible for its inactivation and the shift towards 
a malignant phenotypic [50, 51, 72]. Meanwhile, 
restoration of DACH1 expression sensitizes gastric and 
colorectal cancer cells to docetaxel [50, 51] and enhances 
chemosensitivity to 5-fluorouracil (5-FU) in hepatocellular 
carcinoma [62]. The next logical step would be to search 
for a compound that can induce the expression of DACH1 
in tumor tissues. Intriguingly, 5-Aza-2’-deoxycytidine 
(decitabine), a potent demethylating agent, reactivates 
DACH1 in gastric cancer, suggesting that low-dose 
decitabine combined with traditional chemotherapy may 
improve the efficiency of treatments against tumors in 
which DACH1 expression is silenced [50]. Additionally, 
ectopic expression of miR-217 directly inhibits DACH1 
by binding to its 3’UTR, which not only may exhibit the 
tumorigenic role of miR-217 in breast cancer, but also 
suggests an approach for recovering DACH1 expression 
by diminishing the activation of a particular miRNA [73].
sIX1
The current studies have defined an oncogenic role 
for SIX family members in the development of diverse 
tumor types. SIX1 combined with specific transcription 
factors increases a particular subpopulation of cancer 
stem/progenitor cells. Furthermore, SIX family members 
are directly responsible for the malignant behavior of 
cancer cells [2, 37, 53]. Indeed, SIX1 has been highlighted 
as an independent prognostic marker in colorectal cancer, 
and its profile can be used to stratify patients into different 
risk groups and guide individualized regimens [74]. 
Accumulation of SIX1 reduces paclitaxel sensitivity in 
patients undergoing breast cancer chemotherapy [75], 
and diminishes the therapeutic response to tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) in 
ovarian carcinoma [76]. Intriguingly, overexpression of 
SIX1 reduces p53 abundance and induces resistance to 
molecular therapy targeting the murine double mimute2 
(MDM2)-p53 interaction. Therefore, the expression of 
SIX1 could be used as a molecular marker to predict 
which patients would benefit from MDM2 antagonists 
[40]. 
Perhaps the most critical question is how to inhibit 
the transcription of SIX1 in a controllable and predictable 
manner. Silencing SIX1 expression using short hairpin 
RNA (shRNA) or miRNA is now viewed as a potential 
cancer treatment strategy. For instance, miRNA-185 
directly reduces SIX1 abundance and thereby sensitizes 
SIX1-overexpressing cancer cells to TRAIL-induced 
apoptosis [77]. miR-30b blocks the translation of SIX1 by 
binding to its 3’-UTR, thereby delaying the progression 
of colorectal cancer [78]. Epigenetic modifications, 
including histone acetylation and methylation, can also 
restrain the oncogenic role of SIX1 [79, 80]. Since DNA 
methylation inhibitors (e.g., Dacogen, Vidaza) and broad-
spectrum HDAC inhibitors (e.g., Vorinostat, Romidepsin) 
have been successfully developed, inhibiting epigenetic 
modifications may be an attractive approach for the multi-
modal treatment of advanced cancer [81]. However, it is 
not known whether these small molecule inhibitors of 
epigenetic enzymes can block the function of SIX1 in vivo. 
Although structural and biochemical evidence has 
confirmed that SIX1 is a DNA-binding transcription factor, 
the recruitment of additional corepressors or coactivators 
is necessary for SIX1 signaling [18]. In vertebrates, 
SIX1 requires EYA for its oncogenic function [19]. Thus, 
another way to inhibit the aberrant function of SIX1 is by 
destroying the SIX1/EYA transcriptional complex with a 
small molecule inhibitor. Since the successful discovery 
of small molecules like Nutlin-3, which releases p53 from 
the binding pocket in the MDM2 protein [82], there has 
been greater hope that effective inhibitors of the SIX1/
EYA complex could be generated.
EYA
EYA proteins facilitate tumor progression and are 
independent prognostic factors in breast and ovarian 
cancer [31, 83], but not in pancreatic cancer, in which 
epigenetic silencing of EYA2 increases the cancer invasion 
capacity [84]. The distinct features of the EYA family, 
whose members can function as either transcriptional 
coactivators or tyrosine phosphatases, suggest that 
EYA expression could be inactivated in different ways. 
EYA activity could be regulated by multiple signaling 
pathways. Dr. Li and her coworkers demonstrated 
that hyperactivation of the canonical Wnt and PI3K/
Akt signaling pathways reduces EYA1 ubiquitination 
and thus prevents its premature degradation [85]. In 
particular, PI3K/Akt signaling was shown to repress the 
SUMOylation of EYA1 in a phosphorylation-dependent 
manner and thus enhance the transcriptional activity of 
EYA1 [86]. Since the knockdown of SUMO-activating 
enzyme subunit 2 (SAE2) restrains tumor growth 
and enhances chemosensitivity, it may be possible to 
suppress EYA expression by promoting its SUMOylation 
[87]. Meanwhile, combination regimens with specific 
pathway blockers (PI3K: LY294002; Akt: Perifosine; 
Wnt: XAV939) may be effective treatments for EYA1-
dependent breast cancer.
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Several lines of evidence strongly demonstrate that 
the function of EYA depends on its phosphatase activity; 
therefore, inhibition of this activity may be another 
promising treatment strategy. Designing phosphatase 
inhibitors is challenging, because it requires not only 
detailed information about the three-dimensional structure 
of the protein, but also the identification of a unique 
catalytic property that can be specifically inhibited. In the 
EYA X-ray crystal structure, aspartic acid appears to be 
involved in a metal-dependent reaction, rather than the 
more common cysteine and arginine residues. Thus, EYA 
is distinct from the classical tyrosine phosphatases in the 
HAD family, offering a great chance to identify selective 
EYA phosphatase inhibitors [27, 88, 89]. Seven novel 
classes of compounds, which bind to the active site of 
EYA and chelate the active site Mg2+ ion, were discovered 
through structure-based virtual screening technology [90]. 
Using a structure-based de novo design, Dr. Kim’s group 
further identified 29 inhibitors of EYA2 phosphatase 
with moderate inhibitory activities (IC
50
 values from 6 
to 50 μM) [91]. While the tyrosine-phosphatase activity 
of EYA is critical for regulating the chromatin structure, 
the threonine-phosphatase activity otherwise determines 
the involvement of EYA in the innate immune response, 
and could be inhibited by okadaic acid [28]. However, 
whether the threonine-phosphatase activity of the EYAs 
promotes cancer initiation and progression remains to be 
determined.
Another well-recognized inhibitor of the EYA 
family is Benzbromarone and its derivative, Benzarone, 
which selectively blocks both EYA2 and EYA3 activity in 
a non-competitive way [63, 92]. Pharmacological studies 
and clinical evaluation in gout treatment have provided 
comprehensive insights into the safety, metabolism, 
pharmacokinetics and both chronic and acute toxicity of 
Benzbromarone and Benzarone. Another advantage of 
Benzbromarone and its derivatives is the anti-angiogenic 
effect, which may thereby reduce the neovascular-based 
dissemination of cancer cells [87]. The major metabolite 
of Benzbromarone, 6-hydroxy Benzbromarone, is a more 
powerful inhibitor of EYA tyrosine-phosphatase activity, 
and may block tumor growth by inhibiting angiogenesis 
[92]. As a result of these studies, there is now a discussion 
of whether luminal B-type breast cancer patients could 
benefit from Benzbromarone-based combination therapy 
due to its suppression of EYA [31].
Recently, a fluorescent high-throughput-
screening phosphatase assay identified a series of 
N-arylidenebenzohydrazide-containing compounds 
that inhibit the catalytic site of EYA2 compared 
with other cellular phosphatases in HAD family 
[93]. These compounds selectively inhibit the 
phosphatase activity of EYA2 rather than EYA3 [94]. 
In contrast with those metal-chelating compounds and 
Benzbromarone, which physiologically perturbs metal 
ions, N-arylidenebenzohydrazide-containing compounds 
bind to the allosteric site in a Mg2+-independent manner 
[89]. Since EYA2-induced migration could be reversed 
by these compounds, EYA2 phosphatase-specific anti-
cancer drugs appear promising. With great technological 
advancements, like the establishment of high-throughput 
material screening platforms, it will be possible to find a 
specific EYA inhibitor for clinical application.
cONcLUsION AND PErsPEctIVEs
The RDGN could directly or indirectly determine 
the biological features and clinical outcomes of various 
cancer types, so RDGN genes are promising biomarkers. 
Evaluation of profiles of RDGN members could guide 
the design of individualized treatment regimens [95]. At 
the core of this research area are the questions: Which 
particular cancers are driven by the RDGN? And then, 
how will it be possible to specifically reactivate the 
expression of DACH1 or efficiently block the functions 
of SIX1/EYA? At this time, only a few drugs and small 
molecules have been shown to counteract the aberrant 
expression of RDGN members in vitro. Therapeutic agents 
targeting the RDGN are worthy of development in light of 
the profound biological effects of these gene products in 
cancer progression and metastasis.
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